Docetaxel Plus Trastuzumab as Treatment for Her-2 Positive Metastatic Breast Cancer: Review of the Existing Evidence | Zendy

Gaston Demonty | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Docetaxel Plus Trastuzumab as Treatment for Her-2 Positive Metastatic Breast Cancer: Review of the Existing Evidence

Author(s) -

Gaston Demonty

Publication year - 2007

Publication title -

women s health

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.363

H-Index - 39

eISSN - 1745-5065

pISSN - 1745-5057

DOI - 10.2217/17455057.3.5.523

Subject(s) - trastuzumab , docetaxel , medicine , metastatic breast cancer , cardiotoxicity , oncology , breast cancer , clinical trial , cancer , chemotherapy

The aim of this review is to examine the evidence available supporting the use of the docetaxel plus trastuzumab combination for patients with HER-2-positive metastatic breast cancer. The results of trials involving this combination are summarized, with an emphasis on efficacy and cardiotoxicity data. Finally, this article attempts to identify areas of uncertainty where new trials are warranted to improve our knowledge regarding optimal care for patients with HER-2-positive metastatic breast cancer.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research